

To
The honourable

Mr Demetrios Lintzeris, President of EOF
Mr Georgios Petrikkos, Chairman of the Pricing Committee
Mr Babis Karathanos, Advisor of the Minister of Health
Mrs Eleftheria Nikolaidou, EOF's Department for Medicinal Products Prices

Cc: Mr Adonis Georgiadis, Minister of Health

Re: Correction of errors in the draft Prices Bulletin

Chalandri, February 4, 2014

Dear Sirs and Madam,

In view of the meeting of the Pricing Committee that will be held on Wednesday 5/2/2014 and given that the **draft Prices Bulletin, which has been posted at EOF's website and concerns re-pricing of medicinal products, contains many and severe errors**, we kindly request that you take into account the following.

More specifically, taking into account on one hand, that the Prices Bulletin with the re-pricing of medicinal products must be issued as soon as possible in order to produce the necessary saving, and on the other, due to the large volume of remarks that companies have filed, the Pricing Committee may not be able to examine each of them separately, **it must be primarily approved that the no price of an on-patent medicinal product and no price of a unique medicinal product will be reduced below the average of the three lower prices of the EU countries, in performance of the Ministerial Decision today in force. This is because, the relevant legislation expressly provides that a reference medicinal product is priced as off-patent once the expiration of the protection period (on-patent) for the active substance is documented and not by taking into account the data protection period.**

To that end and in order to facilitate the work of the Pricing Committee, we kindly request that you take into consideration the relevant requests of the companies, in order to evaluate and correct errors, where applicable, **before the session of the Pricing Committee and the issue of the Prices Bulletin.** Once more, we would like to point out that the due and lawful pricing of these products is of high importance in order to secure their adequacy in the market, thus protecting the public health.

Yours sincerely,

Konstantinos M. Frouzis
President

Nikos Kefalas
Vice President